VISTAGEN THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price of $1.56 per share for the 6-month period ending 2017-09-30, per its 10-Q filed 2018-02-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice · last filed 2018-02-12
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, other share increase (decrease) in period, weighted average exercise price for the quarter ending 2016-06-30 was $8.45.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, other share increase (decrease) in period, weighted average exercise price for fiscal 2013 was $1.72.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2017-09-30 | $1.56 10-Q · filed 2018-02-12 | ||||
| 2016-12-31 | $8.45 10-Q · filed 2017-02-13 | ||||
| 2016-09-30 | $4.27 10-Q · filed 2018-02-12 | $8.45 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | $8.45 10-Q · filed 2016-08-12 | ||||
| 2013-03-31 | $1.72 10-K · filed 2014-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |